Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 284
interventional 172
Observational 98
Registry 14

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug|placebo 65
Drug 51
Other 14
Biological|placebo 10
Biological 8
Behavioral 6
Diagnostic Test 4
Dietary Supplement 3
Procedure 3
Biological|Procedure 2
Biological|Drug 1
Biological|Drug|placebo 1
Device 1
Dietary Supplement|placebo 1
Genetic|placebo 1
placebo 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 27
NA 16
United Kingdom 8
Denmark 7
Japan 5
China 4
Germany 4
France 3
Norway 3
Belgium|Bulgaria|Czechia|Estonia|Poland|Spain|Ukraine 2
Brazil 2
Canada 2
Egypt 2
Germany|Netherlands|United Kingdom 2
Netherlands 2
Sweden 2
United States|Canada 2
United States|Czechia|Germany|Hungary|Poland|Russian Federation 2
United States|Puerto Rico 2
Argentina|Australia|Austria|Belgium|Canada|Denmark|Finland|France|Germany|Hungary|India|Israel|Italy|Mexico|Netherlands|Poland|South Africa|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
Argentina|Australia|Austria|Belgium|Czech Republic|Denmark|Finland|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Saudi Arabia|Serbia|Spain|Sweden|Switzerland|Taiwan|Turkey|United Kingdom 1
Australia|Bulgaria|Czechia|Estonia|Hungary|Lithuania|Poland|Russian Federation|Serbia|Slovakia|Spain 1
Bangladesh 1
Belarus|Russian Federation 1
Belgium 1
Belgium|Bosnia and Herzegovina|Bulgaria|Czechia|Estonia|Georgia|Latvia|Poland|Spain|Ukraine 1
Belgium|Bulgaria|Czechia|Estonia|Finland|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Poland|Romania|Russian Federation|Spain|Switzerland|United Kingdom 1
Belgium|Bulgaria|France|Germany|Greece|Hungary|Israel|Italy|Poland|Portugal|Russian Federation|Spain|Ukraine|United Kingdom 1
Belgium|Canada|Germany|Netherlands|United Kingdom 1
Bulgaria|Czechia|Germany|Greece|Italy|Slovakia|Spain|United Kingdom 1
Bulgaria|Estonia|Hungary|Poland|Russian Federation|Ukraine 1
Bulgaria|Moldova, Republic of|United Kingdom 1
Canada|United States|Australia|Belgium|Germany|Hungary|Italy|Japan|Poland|Russian Federation|United Kingdom 1
Colombia|United States|Argentina|Brazil|Canada|Chile|Czechia|France|Germany|Greece|Israel|Italy|Mexico|Peru|Poland|South Africa|Spain 1
Denmark|Finland|Norway|Sweden 1
France|Germany|United States|Argentina|Belgium|Brazil|Canada|Czechia|Hungary|Ireland|Italy|Mexico|Poland|Spain|United Kingdom 1
Germany|United States|Australia|Canada|Czechia|Italy|Japan|Poland|Russian Federation|United Kingdom 1
Hong Kong 1
Hungary|Italy|United States|Argentina|Australia|Canada|Czechia|Germany|Mexico|Poland|Russian Federation|South Africa|Spain 1
India 1
Lithuania|United States|Australia|Belgium|Bulgaria|Canada|Czechia|Estonia|France|Hungary|Italy|Korea, Republic of|New Zealand|Poland|Romania|Russian Federation|Taiwan|United Kingdom 1
Mexico|United States|Argentina|Hungary|Poland|Russian Federation|Spain|Ukraine 1
Portugal 1
Russian Federation|United States|Australia|Belarus|Canada|Germany|Hungary|Lithuania|Poland|Romania|Spain|Ukraine 1
Switzerland|United States|France|Netherlands 1
Turkey 1
United States|Argentina|Australia|Belarus|Belgium|Bosnia and Herzegovina|Brazil|Bulgaria|Canada|Chile|China|Colombia|Croatia|Czechia|Estonia|Germany|Greece|Hong Kong|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Latvia|Lithuania|Malaysia|Mexico|Netherlands|New Zealand|Norway|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Serbia|Singapore|Slovakia|Slovenia|South Africa|Spain|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Belgium|Bosnia and Herzegovina|Brazil|Bulgaria|Canada|Chile|Croatia|Czechia|Denmark|Estonia|Finland|Germany|Greece|Israel|Italy|Korea, Republic of|Latvia|Lithuania|Malaysia|Mexico|Netherlands|New Zealand|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Serbia|Singapore|Slovakia|South Africa|Spain|Sweden|Taiwan|Ukraine|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Czech Republic|Germany|Israel|Italy|Philippines|Poland|Romania|Russian Federation|Singapore|Slovakia|Thailand|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Czechia|Germany|Israel|Italy|Philippines|Poland|Russian Federation|Singapore|Slovakia|Thailand|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Denmark|Estonia|Finland|France|Germany|Greece|Hungary|Israel|Italy|Netherlands|New Zealand|Poland|Portugal|Puerto Rico|Singapore|South Africa|Spain|Sweden|United Kingdom 1
United States|Argentina|Austria|Belgium|Canada|Colombia|Czechia|France|Germany|Hungary|Ireland|Italy|Mexico|Netherlands|Norway|Spain|United Kingdom 1
United States|Argentina|Austria|Canada|Chile|Czechia|Denmark|Estonia|Finland|Germany|Greece|Guatemala|Hungary|India|Ireland|Israel|Italy|Latvia|Lithuania|Mexico|Netherlands|Philippines|Russian Federation|Spain|Sweden|Thailand|United Kingdom|Vietnam 1
United States|Australia|Austria|Canada|Finland|Germany|Hungary|Latvia|Lithuania|New Zealand|Poland|Russian Federation|Spain|United Kingdom 1
United States|Australia|Austria|Canada|France|Germany|Hungary|New Zealand|Poland|Russian Federation|South Africa|Spain|United Kingdom 1
United States|Australia|Belgium|Brazil|Bulgaria|Canada|Czechia|Germany|Hungary|Mexico|Poland|Russian Federation|Slovakia|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|Chile|Czechia|France|Greece|Hungary|Italy|Japan|Korea, Republic of|Netherlands|New Zealand|Portugal|Puerto Rico|Spain|United Kingdom 1
United States|Australia|Belgium|Brazil|Czechia|France|Germany|Mexico|Poland|Russian Federation|Slovakia|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Bulgaria|Canada|Czechia|France|Germany|Hungary|Mexico|Poland|Russian Federation|Slovakia|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Bulgaria|Canada|Czechia|France|Germany|Italy|Poland|Russian Federation|Sweden|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Estonia|Germany|Hungary|Latvia|Netherlands|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|France|Germany|Hungary|Italy|Japan|Poland|Russian Federation|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Germany|Poland|Puerto Rico|Russian Federation|Thailand|United Kingdom 1
United States|Australia|Brazil|Bulgaria|Canada|Colombia|Czechia|Germany|Italy|Poland|Puerto Rico|Qatar|Spain|United Kingdom 1
United States|Australia|Bulgaria|Canada|Czechia|Denmark|Estonia|Finland|France|Germany|Greece|Hungary|Iceland|India|Israel|Italy|Korea, Republic of|Latvia|Lithuania|Netherlands|Poland|Portugal|Russian Federation|Slovakia|Spain|United Kingdom 1
United States|Australia|Bulgaria|Canada|Czechia|Germany|Italy|Netherlands|Puerto Rico|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Australia|Canada|Czechia|Estonia|Hungary|New Zealand|Romania|Russian Federation|Spain 1
United States|Australia|Canada|Czechia|Germany|Hungary|Korea, Republic of|Malaysia|Poland|Russian Federation|Spain|Taiwan|Ukraine 1
United States|Australia|Canada|Czechia|Germany|Japan|Poland|Russian Federation 1
United States|Australia|Canada|Finland|France|Germany|Italy|Korea, Republic of|Lithuania|Poland|Romania|Russian Federation|Slovakia|Spain|Switzerland|United Kingdom 1
United States|Australia|Canada|Germany|Hungary|Korea, Republic of|Poland|Russian Federation|United Kingdom 1
United States|Australia|Czechia|France|Germany|Italy|Poland|Spain|Taiwan|United Kingdom 1
United States|Australia|New Zealand 1
United States|Austria|Belgium|Canada|Denmark|Germany|Italy|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Austria|Belgium|Canada|France|Germany|Italy|Netherlands|Russian Federation|Spain|United Kingdom 1
United States|Austria|Canada|France|Germany|Hungary|Poland|Russian Federation|Sweden|United Kingdom 1
United States|Belgium|Bulgaria|Canada|Czechia|Estonia|France|Germany|Hungary|Italy|Poland|Russian Federation|South Africa|Spain|Taiwan|United Kingdom 1
United States|Belgium|Bulgaria|Canada|Czechia|Estonia|France|Japan|Mexico|Netherlands|Poland|Russian Federation|Spain|Ukraine|United Kingdom 1
United States|Belgium|Canada|Denmark|France|Germany|Hungary 1
United States|Belgium|Canada|Poland|Spain|United Kingdom 1
United States|Belgium|Germany|Italy|Poland|Russian Federation|South Africa|Spain|Turkey|United Kingdom 1
United States|Belgium|Germany|Italy|Poland|Russian Federation|Spain|Turkey 1
United States|Bulgaria|Czechia|Estonia|Latvia|Lithuania|Malaysia|Poland|Russian Federation|Spain|Taiwan|Turkey|Ukraine 1
United States|Bulgaria|Czechia|Estonia|Mexico|Poland|Russian Federation|Slovakia|South Africa|Spain|Ukraine|United Kingdom 1
United States|Canada|Denmark|Finland|Switzerland 1
United States|Canada|France|Germany|Greece|Hungary|Latvia|Mexico|Poland|Russian Federation 1
United States|Canada|Germany|Poland|Romania|Russian Federation|Spain 1
United States|Canada|Germany|Poland|Russian Federation 1
United States|Czechia|Germany|Hungary|Italy|Poland|Russian Federation|Spain|United Kingdom 1
United States|Czechia|Germany|Poland|Russian Federation 1
United States|Czechia|Russian Federation 1
United States|Hungary|Argentina|Bulgaria|Canada|Chile|Czechia|France|Greece|Latvia|Mexico|Poland|Portugal|Puerto Rico|Russian Federation|South Africa|Spain|United Kingdom 1
United States|Japan 1
United States|Netherlands|Switzerland 1

Sites per Study

Site_count Study_Count
1 63
2 11
3 3
4 3
6 2
7 2
8 2
9 3
10 2
11 2
13 1
16 2
18 2
19 1
21 1
22 2
25 3
27 1
30 2
32 1
33 1
34 1
36 1
38 1
40 1
41 2
42 2
44 1
45 1
48 1
49 1
52 1
53 1
56 1
57 1
59 1
60 1
64 1
71 1
73 1
76 1
77 2
82 3
83 1
88 1
89 1
91 1
92 3
94 1
95 1
98 1
101 1
103 1
105 2
106 1
109 2
116 1
117 3
118 1
123 1
125 1
131 1
138 2
139 1
153 1
155 1
165 1
168 1
172 1
257 1
347 1

Phase

Phase Study_Count
Phase 3 73
N/A 32
Phase 2 29
Phase 4 21
Phase 1 14
Early Phase 1 1
Phase 1/Phase 2 1
Phase 2/Phase 3 1

Number of Arms

Number_of_Arms Count_of_Studies
1 28
2 74
3 26
4 16
5 9
6 4
7 2
25 1
NA 12

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 68 13.0000 6.00000 120 20.0000 540 51.0000 10.00
1st Qu. 68 55.7500 20.25000 120 122.0000 540 195.0000 48.00
Median 68 100.0000 41.00000 120 180.0000 540 390.0000 115.00
Mean 68 715.4062 56.85714 120 173.4828 540 395.6164 237.15
3rd Qu. 68 209.2500 51.25000 120 217.0000 540 489.0000 318.75
Max. 68 18000.0000 216.00000 120 617.0000 540 1705.0000 1013.00

Trial Group Type

group_type Group_Count
Experimental 248
Placebo Comparator 77
Active Comparator 65
Other 27
NA 12
No Intervention 8
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Parallel Assignment 124
Single Group Assignment 40
Crossover Assignment 5
NA 2
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 144
Other 6
Supportive Care 6
Basic Science 5
Diagnostic 4
Prevention 4
NA 2
Screening 1

Observational Studies

Studies by Country

Country Study_Count
NA 18
France 12
United States 12
United Kingdom 7
Germany 6
Canada 5
Spain 4
Italy 3
Australia 2
Austria 2
Belgium 2
Denmark 2
Japan 2
Korea, Republic of 2
Netherlands 2
Russian Federation 2
Sweden 2
Australia|China|Korea, Republic of 1
Belgium|France|Greece|Netherlands|Russian Federation|Spain|United Kingdom 1
Bulgaria|Canada|Czechia|Germany|Greece|Spain|United Kingdom 1
Colombia 1
Croatia|Hungary|Israel|Poland|Romania|Slovakia|Ukraine 1
Germany|United Kingdom 1
Greece 1
Norway 1
Philippines 1
Portugal 1
Saudi Arabia|Kuwait|Qatar|Algeria|Egypt 1
Turkey 1
United States|Argentina|Australia|Austria|Belgium|Canada|Chile|Colombia|Czechia|Greece|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Portugal|Slovakia|Slovenia|Spain|Sweden|Taiwan|Ukraine 1

Sites per Study

Site_count Study_Count
1 62
2 3
3 1
4 3
5 1
8 1
9 3
10 2
12 1
14 1
15 3
19 1
20 1
21 1
22 2
38 1
41 1
43 1
47 1
68 1
77 1
80 1
163 1
180 1
432 1
509 1
634 1

Enrollment Metrics

Measure Observational
Min 12.000
1st Qu 107.000
Median 250.000
Mean 3901.433
3rd Qu 809.000
Max 266890.000

Observation Model

observational_model Study_Count
Cohort 65
Case-Only 15
Case-Control 7
NA 6
Case Control 2
Other 2
Case-Crossover 1

Time Perspective

time_perspective Study_Count
Prospective 81
Cross-Sectional 8
Retrospective 5
NA 2
Cross-Sectional, Retrospective/Prospective 1
Other 1

Registries

Studies by Country

Country Study_Count
United States 4
Denmark 3
Australia 1
Brazil|Canada|United States|Austria|Estonia|France|Germany|Italy|Romania|Russian Federation|Singapore|Spain|Turkey|United Kingdom 1
Canada 1
Germany 1
Italy 1
Korea, Republic of 1
NA 1

Sites per Study

Site_count Study_Count
1 10
3 1
11 1
22 2

Enrollment Metrics

Measure Registries
Min 110.000
1st Qu 356.500
Median 4250.000
Mean 8165.429
3rd Qu 6500.000
Max 57053.000

Registry Model

observational_model Study_Count
Cohort 11
Case-Control 1
Case-Only 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 12
Cross-Sectional 1
Other 1

Follow-up

target_duration Study_Count
10 Years 3
2 Years 2
5 Years 2
1 Day 1
12 Months 1
15 Years 1
16 Weeks 1
24 Years 1
3 Years 1
6 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03733925 A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03733925 Recruiting Johnson & Johnson Private Limited 2021-01-25
NCT04314544 Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) https://ClinicalTrials.gov/show/NCT04314544 Recruiting Sun Pharma Global FZE 2021-08-11
NCT04314531 Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) https://ClinicalTrials.gov/show/NCT04314531 Recruiting Sun Pharma Global FZE 2021-05-12
NCT04163016 A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) https://ClinicalTrials.gov/show/NCT04163016 Recruiting UCB Pharma 2022-08-31
NCT04109976 A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT04109976 Enrolling by invitation UCB Pharma 2021-01-31
NCT04009499 A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT04009499 Enrolling by invitation UCB Pharma 2024-10-31
NCT03796858 A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy https://ClinicalTrials.gov/show/NCT03796858 Active, not recruiting Janssen Pharmaceutica N.V., Belgium 2020-11-30
NCT03486457 Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03486457 Recruiting Pfizer 2021-06-30
NCT03410992 A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis https://ClinicalTrials.gov/show/NCT03410992 Active, not recruiting UCB Pharma 2018-12-28
NCT03409211 Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03409211 Recruiting NYU Langone Health 2023-12-31
NCT03402087 A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients https://ClinicalTrials.gov/show/NCT03402087 Completed Bristol-Myers Squibb 2018-03-20
NCT03370133 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis https://ClinicalTrials.gov/show/NCT03370133 Completed UCB Pharma 2019-01-08
NCT03320876 An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. https://ClinicalTrials.gov/show/NCT03320876 Active, not recruiting Galapagos NV 2024-01-31
NCT03262727 The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients https://ClinicalTrials.gov/show/NCT03262727 Completed Bristol-Myers Squibb 2017-11-23
NCT03254784 A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation https://ClinicalTrials.gov/show/NCT03254784 Completed Bristol-Myers Squibb 2017-11-04
NCT03248518 Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases https://ClinicalTrials.gov/show/NCT03248518 Active, not recruiting University of Aberdeen 2020-10-31
NCT03162796 A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) https://ClinicalTrials.gov/show/NCT03162796 Completed Janssen Research & Development, LLC 2019-03-14
NCT03158285 A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03158285 Active, not recruiting Janssen Research & Development, LLC 2019-02-25
NCT03151551 A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03151551 Completed Eli Lilly and Company 2018-11-15
NCT03148860 Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA https://ClinicalTrials.gov/show/NCT03148860 Recruiting Fraunhofer Institute for Molecular Biology and Applied Ecology 2020-12-30
NCT03142503 The DIET Trial - Dietetic Intervention in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03142503 Completed Federal University of São Paulo 2015-03-16
NCT03104400 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug https://ClinicalTrials.gov/show/NCT03104400 Active, not recruiting AbbVie 2019-09-20
NCT03104374 A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug https://ClinicalTrials.gov/show/NCT03104374 Active, not recruiting AbbVie 2019-07-17
NCT03101670 A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03101670 Completed Galapagos NV 2018-03-12
NCT03058900 Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03058900 Active, not recruiting Odense University Hospital 2020-07-01
NCT03031782 Secukinumab Safety and Efficacy in JPsA and ERA https://ClinicalTrials.gov/show/NCT03031782 Active, not recruiting Novartis 2020-06-16
NCT03008590 Low Dose Naltrexone for Chronic Pain From Arthritis https://ClinicalTrials.gov/show/NCT03008590 Completed VA Office of Research and Development 2019-12-31
NCT02995460 Interval Training Study in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02995460 Completed Norwegian University of Science and Technology 2015-12-31
NCT02986373 A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171) https://ClinicalTrials.gov/show/NCT02986373 Completed AbbVie 2018-07-08
NCT02986139 Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02986139 Completed Amgen 2017-09-08
NCT02980692 Efficacy and Safety Study of SUNPG1623 https://ClinicalTrials.gov/show/NCT02980692 Completed Sun Pharma Global FZE 2019-03-01
NCT02969525 A Multicenter Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis. https://ClinicalTrials.gov/show/NCT02969525 Completed UCB Pharma 2017-11-30
NCT02917434 Effects of Weight-loss Treatment in Obese Patients With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02917434 Active, not recruiting Vastra Gotaland Region 2019-12-12
NCT02912221 Stepping Up For Inflammatory Arthritis https://ClinicalTrials.gov/show/NCT02912221 Active, not recruiting University of Pennsylvania 2020-11-30
NCT02854163 Effect of Secukinumab in the Treatment of Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02854163 Completed University of Liverpool 2019-09-18
NCT02814175 A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL) https://ClinicalTrials.gov/show/NCT02814175 Completed AbbVie 2019-09-23
NCT02798211 Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo https://ClinicalTrials.gov/show/NCT02798211 Completed Novartis 2018-12-05
NCT02772601 This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02772601 Completed AbbVie 2017-06-15
NCT02771210 Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site https://ClinicalTrials.gov/show/NCT02771210 Completed Novartis 2019-12-11
NCT02745080 Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02745080 Completed Novartis 2019-12-30
NCT02721966 Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement https://ClinicalTrials.gov/show/NCT02721966 Completed Novartis 2019-06-26
NCT02719171 BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02719171 Completed AbbVie 2017-05-31
NCT02714322 MYL-1401A Efficacy and Safety Comparability Study to Humira® https://ClinicalTrials.gov/show/NCT02714322 Completed Mylan Inc. 2016-05-31
NCT02662985 Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) https://ClinicalTrials.gov/show/NCT02662985 Recruiting Novartis 2020-11-23
NCT02598739 Evaluation of the Effectiveness of Resistance Training in Patients With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02598739 Completed Federal University of São Paulo 2014-09-30
NCT02584855 A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02584855 Completed Eli Lilly and Company 2018-10-30
NCT03926195 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis https://ClinicalTrials.gov/show/NCT03926195 Recruiting Galapagos NV 2021-01-31
NCT02538341 Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) https://ClinicalTrials.gov/show/NCT02538341 Active, not recruiting University of Alabama at Birmingham 2019-01-31
NCT02483234 Psoriasis-Arthritis & Bone Program https://ClinicalTrials.gov/show/NCT02483234 Completed University of Erlangen-Nürnberg Medical School 2018-06-30
NCT02436785 Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? https://ClinicalTrials.gov/show/NCT02436785 Completed University of British Columbia 2017-12-31
NCT02404350 Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02404350 Completed Novartis 2017-08-16
NCT02376790 Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02376790 Completed Amgen 2018-01-09
NCT02349451 A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) https://ClinicalTrials.gov/show/NCT02349451 Completed AbbVie 2016-07-04
NCT02319759 Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) https://ClinicalTrials.gov/show/NCT02319759 Completed Janssen Research & Development, LLC 2016-05-31
NCT02294227 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02294227 Completed Novartis 2016-02-16
NCT02267642 A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02267642 Completed AbGenomics B.V Taiwan Branch 2015-10-31
NCT02232321 Vascular Effects of Achieving Minimal Disease Activity in Psoriatic Arthritis - a 2 Year Prospective Cohort Study https://ClinicalTrials.gov/show/NCT02232321 Completed Chinese University of Hong Kong 2017-10-31
NCT02188654 Metformin in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02188654 Completed University of Alexandria 2014-03-31
NCT02188641 Effect of Exercise and Diet on Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02188641 Completed University of Alexandria 2014-07-31
NCT02181673 A Study of Golimumab in Participants With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02181673 Completed Janssen Research & Development, LLC 2016-05-05
NCT02164214 Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? https://ClinicalTrials.gov/show/NCT02164214 Completed Assistance Publique Hopitaux De Marseille 2015-03-31
NCT02154425 A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers https://ClinicalTrials.gov/show/NCT02154425 Completed UCB Pharma 2015-12-31
NCT02148640 The NOR-SWITCH Study https://ClinicalTrials.gov/show/NCT02148640 Completed Diakonhjemmet Hospital 2016-06-30
NCT02141763 Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02141763 Completed UCB Pharma 2015-08-31
NCT02098694 Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis https://ClinicalTrials.gov/show/NCT02098694 Completed Norwegian University of Science and Technology 2015-04-30
NCT02065713 Efficacy of Golimumab in Combination With Methotrexate (Mtx) Versus Mtx Monotherapy, in Improving Dactylitis, in Mtx naïve Psoriatic Arthritis Patients https://ClinicalTrials.gov/show/NCT02065713 Completed Instituto de Medicina Molecular João Lobo Antunes 2017-06-30
NCT01307423 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) https://ClinicalTrials.gov/show/NCT01307423 Completed Amgen 2013-02-21
NCT02052609 A Phase 3 Clinical Study of KHK 4827 https://ClinicalTrials.gov/show/NCT02052609 Completed Kyowa Kirin Co., Ltd. 2015-01-28
NCT03896581 A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03896581 Recruiting UCB Pharma 2021-02-28
NCT03357471 Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn’s Disease https://ClinicalTrials.gov/show/NCT03357471 Completed UCB Pharma 2018-07-02
NCT03895203 A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03895203 Recruiting UCB Pharma 2021-07-31
NCT02349295 A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02349295 Completed Eli Lilly and Company 2016-09-09
NCT01989468 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01989468 Completed Novartis 2015-05-27
NCT01988103 Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis https://ClinicalTrials.gov/show/NCT01988103 Completed Amgen 2014-11-20
NCT01976364 Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01976364 Completed Pfizer 2019-05-20
NCT01925768 Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01925768 Completed Amgen 2015-02-25
NCT01901185 Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept https://ClinicalTrials.gov/show/NCT01901185 Completed Amgen 2013-12-18
NCT01892436 Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01892436 Completed Novartis 2018-01-11
NCT01882439 Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors https://ClinicalTrials.gov/show/NCT01882439 Completed Pfizer 2016-04-30
NCT01871649 Initial Treatment With Golimumab in Early PsA https://ClinicalTrials.gov/show/NCT01871649 Completed Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 2018-11-30
NCT01852851 Employment and Arthritis: Making it Work https://ClinicalTrials.gov/show/NCT01852851 Active, not recruiting University of British Columbia 2020-06-30
NCT01818804 The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01818804 Completed Aalborg University Hospital 2015-12-31
NCT01752634 Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01752634 Completed Novartis 2014-05-12
NCT01695239 A Study of Ixekizumab in Participants With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01695239 Completed Eli Lilly and Company 2014-12-31
NCT01690299 Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis https://ClinicalTrials.gov/show/NCT01690299 Completed Amgen 2014-07-03
NCT01680159 A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis https://ClinicalTrials.gov/show/NCT01680159 Completed Mitsubishi Tanabe Pharma Corporation 2015-03-31
NCT02024646 Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02024646 Completed Amgen 2015-10-31
NCT01519089 A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01519089 Completed Pfizer 2014-01-31
NCT01490450 Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy https://ClinicalTrials.gov/show/NCT01490450 Completed Vitaeris INC 2013-06-30
NCT01465438 HUmira in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01465438 Completed Glostrup University Hospital, Copenhagen 2011-06-30
NCT01463189 Web-based Support to Manage Arthritis Pain https://ClinicalTrials.gov/show/NCT01463189 Completed Inflexxion, Inc. 2012-11-30
NCT01392326 Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) https://ClinicalTrials.gov/show/NCT01392326 Completed Novartis 2014-10-31
NCT04304326 Comparison of the Effectiveness of Functional Training Versus Resistance Exercises in Patients With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT04304326 Recruiting Federal University of São Paulo 2020-04-02
NCT04261010 TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_(TIGERS) Study https://ClinicalTrials.gov/show/NCT04261010 Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2022-01-31
NCT04209205 Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT04209205 Recruiting Novartis 2021-04-23
NCT04200690 Effectiveness of Interdisciplinary Care Compared to Usual Care in Patients With Immune-Mediated Inflammatory Diseases https://ClinicalTrials.gov/show/NCT04200690 Recruiting University of Aarhus 2022-07-31
NCT04183881 A Phase 4 Clinical Study of Brodalumab https://ClinicalTrials.gov/show/NCT04183881 Completed Kyowa Kirin Co., Ltd. 2017-01-10
NCT04173039 Anti-Carbamylated Protein Antibodies in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT04173039 Completed Association pour la Recherche Clinique et Immunologique 2019-04-24
NCT04152759 Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects https://ClinicalTrials.gov/show/NCT04152759 Recruiting Bio-Thera Solutions 2020-04-01
NCT04115839 Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy https://ClinicalTrials.gov/show/NCT04115839 Recruiting Gilead Sciences 2022-02-28
NCT04115748 Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy https://ClinicalTrials.gov/show/NCT04115748 Active, not recruiting Gilead Sciences 2022-03-31
NCT04110522 Psoriatic Arthritis D2P Screening https://ClinicalTrials.gov/show/NCT04110522 Recruiting University of Utah 2022-01-31
NCT04108468 GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA (GOLMEPsA) https://ClinicalTrials.gov/show/NCT04108468 Recruiting The Leeds Teaching Hospitals NHS Trust 2021-03-31
NCT04106804 Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker https://ClinicalTrials.gov/show/NCT04106804 Recruiting University of Erlangen-Nürnberg Medical School 2021-08-31
NCT04065958 Yoga-mindfulness for Chronic Arthritis Patients With Persistent Pain https://ClinicalTrials.gov/show/NCT04065958 Recruiting Karolinska Institutet 2021-06-30
NCT04018599 Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS https://ClinicalTrials.gov/show/NCT04018599 Completed Fresenius Kabi SwissBioSim GmbH 2020-03-17
NCT04014413 Safety and Efficacy of Fecal Microbiota Transplantation https://ClinicalTrials.gov/show/NCT04014413 Recruiting Chinese University of Hong Kong 2023-10-31
NCT03963401 A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03963401 Active, not recruiting Pfizer 2020-04-06
NCT03942783 WORKWELL: Testing Work Advice for People With Arthritis https://ClinicalTrials.gov/show/NCT03942783 Recruiting University of Salford 2021-07-30
NCT03932110 Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels https://ClinicalTrials.gov/show/NCT03932110 Completed Istanbul Medeniyet University 2019-06-01
NCT03881059 Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) https://ClinicalTrials.gov/show/NCT03881059 Active, not recruiting Bristol-Myers Squibb 2021-01-28
NCT03347110 A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03347110 Active, not recruiting UCB Pharma 2020-11-30
NCT03853395 BIOTIPRA: BIOmarker-guided Treatment Decisions In Psoriatic and Rheumatoid Arthritis https://ClinicalTrials.gov/show/NCT03853395 Recruiting University of Manchester 2021-02-28
NCT03797872 Psoriatic Oligoarthritis Intervention With Symptomatic thErapy https://ClinicalTrials.gov/show/NCT03797872 Recruiting University of Oxford 2021-09-30
NCT03783026 A Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03783026 Recruiting Amgen 2021-06-01
NCT03769168 An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) https://ClinicalTrials.gov/show/NCT03769168 Recruiting Novartis 2024-10-02
NCT03747939 Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. https://ClinicalTrials.gov/show/NCT03747939 Recruiting Amgen 2021-01-28
NCT03739853 Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial https://ClinicalTrials.gov/show/NCT03739853 Recruiting University of Oxford 2022-02-28
NCT03737045 Psoriatic Arthritis and Psoriasis Treatment Decision Aid https://ClinicalTrials.gov/show/NCT03737045 Recruiting University of Pennsylvania 2020-12-01
NCT03693833 CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis. https://ClinicalTrials.gov/show/NCT03693833 Recruiting Aalborg University Hospital 2020-12-01
NCT03675308 A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy https://ClinicalTrials.gov/show/NCT03675308 Active, not recruiting AbbVie 2020-10-01
NCT03671148 A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) https://ClinicalTrials.gov/show/NCT03671148 Active, not recruiting AbbVie 2020-06-19
NCT03626038 PMCF Study of the A.L.P.S. Proximal Humerus Plating System https://ClinicalTrials.gov/show/NCT03626038 Recruiting Zimmer Biomet 2021-01-31
NCT03598751 Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03598751 Active, not recruiting Biocad 2020-04-30
NCT03552276 A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis. https://ClinicalTrials.gov/show/NCT03552276 Active, not recruiting Sun Pharma Global FZE 2023-06-30
NCT03486613 PROM Collected Via a Smartphone App Versus a Touch Screen Solution Among Patients With Inflammatory Arthritis https://ClinicalTrials.gov/show/NCT03486613 Completed Aalborg University Hospital 2019-09-12
NCT03455166 Identification of New Prognostic Markers in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03455166 Completed Istituto Ortopedico Galeazzi 2016-04-30
NCT03419650 Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) https://ClinicalTrials.gov/show/NCT03419650 Active, not recruiting IRIS Research and Development, LLC 2020-10-31
NCT01212770 PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01212770 Completed Amgen 2012-08-21
NCT01212757 PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01212757 Completed Amgen 2012-07-26
NCT01199809 A Study of RO5310074 in Patients With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01199809 Completed Hoffmann-La Roche 2012-02-29
NCT01198509 Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA) https://ClinicalTrials.gov/show/NCT01198509 Completed NYU Langone Health 2013-01-31
NCT01172938 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01172938 Completed Amgen 2012-04-27
NCT01169844 Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01169844 Completed Novartis 2012-11-30
NCT01147874 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice https://ClinicalTrials.gov/show/NCT01147874 Completed Pfizer 2011-07-31
NCT01106079 TIght COntrol of Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01106079 Completed University of Leeds 2012-07-31
NCT01087788 Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01087788 Completed UCB Pharma 2011-11-30
NCT01077362 A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents https://ClinicalTrials.gov/show/NCT01077362 Completed Janssen Research & Development, LLC 2012-03-31
NCT01009086 A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01009086 Completed Janssen Research & Development, LLC 2011-10-31
NCT00946686 To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions https://ClinicalTrials.gov/show/NCT00946686 Completed Sandoz 2002-09-30
NCT03736161 Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03736161 Completed Globe Pharmaceuticals Limited 2019-09-28
NCT02849795 Evaluation of Adipokines and Fat Tissue in Psoriasis and Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02849795 Completed Centre Hospitalier Universitaire de Besancon 2017-10-17
NCT00809614 Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00809614 Completed Novartis 2010-12-31
NCT01877668 Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study https://ClinicalTrials.gov/show/NCT01877668 Completed Pfizer 2015-12-18
NCT03074656 The Norwegian Drug Monitoring Study https://ClinicalTrials.gov/show/NCT03074656 Active, not recruiting Diakonhjemmet Hospital 2021-01-01
NCT02019602 A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta https://ClinicalTrials.gov/show/NCT02019602 Completed UCB Pharma 2016-10-31
NCT01860976 Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01860976 Active, not recruiting Bristol-Myers Squibb 2015-07-14
NCT00659412 A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00659412 Completed Astellas Pharma Inc 2005-03-31
NCT00646386 Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00646386 Completed Abbott 2004-04-30
NCT00646178 Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy https://ClinicalTrials.gov/show/NCT00646178 Completed Abbott 2004-03-31
NCT00643526 A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector https://ClinicalTrials.gov/show/NCT00643526 Completed Centocor, Inc. 2008-01-31
NCT00509678 Rituxan With or Without Methotrexate in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00509678 Completed Swedish Medical Center 2010-01-31
NCT00462072 Centocor Microarray Study of Patients https://ClinicalTrials.gov/show/NCT00462072 Completed University of Rochester 2010-06-30
NCT00456092 Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00456092 Completed Amgen 2009-05-09
NCT00432406 Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00432406 Completed Chinese University of Hong Kong 2009-03-31
NCT00367237 Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) https://ClinicalTrials.gov/show/NCT00367237 Completed Merck Sharp & Dohme Corp. 2008-03-31
NCT00317499 Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis https://ClinicalTrials.gov/show/NCT00317499 Completed Amgen 2002-06-30
NCT00267956 An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00267956 Completed Centocor, Inc. 2007-03-31
NCT00265096 A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00265096 Completed Centocor, Inc. 2007-05-31
NCT00245960 Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00245960 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2008-05-31
NCT00235885 Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) https://ClinicalTrials.gov/show/NCT00235885 Completed Abbott NA
NCT00195689 Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00195689 Completed Abbott NA
NCT00161655 Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis https://ClinicalTrials.gov/show/NCT00161655 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2006-08-31
NCT00133315 TNFalfa Blocking Treatment of Spondylarthropathies https://ClinicalTrials.gov/show/NCT00133315 Completed Hvidovre University Hospital NA
NCT00127842 REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®) https://ClinicalTrials.gov/show/NCT00127842 Completed Amgen 2005-08-31
NCT00126724 Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects https://ClinicalTrials.gov/show/NCT00126724 Completed Targeted Genetics Corporation 2008-10-31
NCT00111124 Enbrel® in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00111124 Completed Amgen NA
NCT00051662 Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00051662 Completed XOMA (US) LLC NA
NCT00051623 A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00051623 Completed Centocor, Inc. NA
NCT00001422 A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00001422 Completed National Institutes of Health Clinical Center (CC) NA
NCT00023205 Impact of Literacy Level on Patient Education and Health Among People With Arthritis https://ClinicalTrials.gov/show/NCT00023205 Completed Brigham and Women’s Hospital 2006-08-31
NCT00427362 A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM) https://ClinicalTrials.gov/show/NCT00427362 Completed Abbott 2007-05-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02028169 To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA) https://ClinicalTrials.gov/show/NCT02028169 Completed AbbVie 2016-04-30
NCT03399708 Immune Metabolic Associations in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03399708 Completed NHS Greater Glasgow and Clyde 2019-10-12
NCT03823924 Changes in Body Composition Under Ustekinumab in PsA https://ClinicalTrials.gov/show/NCT03823924 Recruiting University Hospital, Lille 2022-07-31
NCT03336281 A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab https://ClinicalTrials.gov/show/NCT03336281 Completed Janssen Cilag S.A.S. 2020-04-07
NCT03330769 Ultrasound in Psoriatic Arthritis Treatment https://ClinicalTrials.gov/show/NCT03330769 Recruiting University of Cagliari 2020-02-28
NCT03248284 Immune-Competent Cell Manifestations in Psoriatic Arthritis Achilles Tendons https://ClinicalTrials.gov/show/NCT03248284 Recruiting Odense University Hospital 2021-06-21
NCT03223012 Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service https://ClinicalTrials.gov/show/NCT03223012 Completed AbbVie 2019-02-28
NCT03106051 Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions https://ClinicalTrials.gov/show/NCT03106051 Active, not recruiting Amgen 2018-07-31
NCT03011242 DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA https://ClinicalTrials.gov/show/NCT03011242 Recruiting University of Rochester 2020-08-31
NCT03006198 Tracking Biologics Along the Silk Road https://ClinicalTrials.gov/show/NCT03006198 Completed Janssen Pharmaceutica N.V., Belgium 2018-12-01
NCT02988674 A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation https://ClinicalTrials.gov/show/NCT02988674 Completed AbbVie 2019-10-16
NCT02984020 Korean Post-marketing Surveillance for Xeljanz https://ClinicalTrials.gov/show/NCT02984020 Recruiting Pfizer 2020-06-09
NCT02925338 National Observational Study On The Use Of Inflectraâ„¢ An Infliximab Biosimilar In Real Life https://ClinicalTrials.gov/show/NCT02925338 Recruiting Pfizer 2020-09-23
NCT02886689 C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France https://ClinicalTrials.gov/show/NCT02886689 Completed Central Hospital, Nancy, France 2010-12-31
NCT02875184 A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands https://ClinicalTrials.gov/show/NCT02875184 Recruiting Amgen 2022-06-30
NCT02750800 Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie’s Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE) https://ClinicalTrials.gov/show/NCT02750800 Completed AbbVie 2018-04-03
NCT02605642 Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade https://ClinicalTrials.gov/show/NCT02605642 Completed Pfizer 2018-12-31
NCT00508547 Psoriasis Longitudinal Assessment and Registry (PSOLAR) https://ClinicalTrials.gov/show/NCT00508547 Recruiting Janssen Scientific Affairs, LLC 2021-05-31
NCT03396679 Disparity Between Ultrasound- and Clinical Findings in Psoriatic Arthritis in Remission https://ClinicalTrials.gov/show/NCT03396679 Completed University Hospital, Montpellier 2018-06-29
NCT02556034 Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA. https://ClinicalTrials.gov/show/NCT02556034 Completed Centre de Rhumatologie de l’Est du Québec 2018-11-16
NCT02486302 A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis. https://ClinicalTrials.gov/show/NCT02486302 Completed Pfizer 2017-12-11
NCT02470481 A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics https://ClinicalTrials.gov/show/NCT02470481 Completed Janssen Research & Development, LLC 2016-07-31
NCT02414633 Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI]) https://ClinicalTrials.gov/show/NCT02414633 Completed AbbVie 2017-03-13
NCT02413749 DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA https://ClinicalTrials.gov/show/NCT02413749 Completed University of Rochester 2016-12-28
NCT02402894 Follow-up of Person-centered Care of Young Adults With Rheumatic Disease https://ClinicalTrials.gov/show/NCT02402894 Active, not recruiting Vastra Gotaland Region 2020-12-31
NCT02361385 PBR28 PET and Inflammatory Arthritis https://ClinicalTrials.gov/show/NCT02361385 Completed University of Oxford 2017-07-31
NCT01316224 Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment https://ClinicalTrials.gov/show/NCT01316224 Completed AbbVie 2014-04-30
NCT01313858 A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554) https://ClinicalTrials.gov/show/NCT01313858 Completed Merck Sharp & Dohme Corp. 2015-09-30
NCT01282372 Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab https://ClinicalTrials.gov/show/NCT01282372 Completed AbbVie 2014-07-31
NCT01273519 Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab https://ClinicalTrials.gov/show/NCT01273519 Completed AbbVie 2013-01-31
NCT03378336 Psoriatic Arthritis Research Collaborative: Biologic Sub-Study https://ClinicalTrials.gov/show/NCT03378336 Recruiting University of Pennsylvania 2021-01-01
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT01845818 Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium https://ClinicalTrials.gov/show/NCT01845818 Completed AbbVie 2017-06-23
NCT01833468 Functional Limitations Due To The Foot Involvement In Spondyloarthritis https://ClinicalTrials.gov/show/NCT01833468 Completed Vakif Gureba Training and Research Hospital 2013-04-30
NCT01797224 OTIS Autoimmune Diseases in Pregnancy Project https://ClinicalTrials.gov/show/NCT01797224 Recruiting University of California, San Diego 2020-01-31
NCT01768858 Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn’s Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT01768858 Completed AbbVie 2017-08-13
NCT01654198 PET/CT in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01654198 Completed University of Pennsylvania 2020-05-31
NCT01559038 Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01559038 Completed AbbVie 2019-11-19
NCT01474876 Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01474876 Completed AbbVie 2014-05-31
NCT04426747 Impact of Barriers and Facilitators to Physical Activity in Patients With Inflammatory Arthritis https://ClinicalTrials.gov/show/NCT04426747 Recruiting Groupe Hospitalier Pitie-Salpetriere 2019-11-16
NCT04345159 Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease https://ClinicalTrials.gov/show/NCT04345159 Active, not recruiting Fondation Ophtalmologique Adolphe de Rothschild 2020-04-30
NCT04335747 COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases https://ClinicalTrials.gov/show/NCT04335747 Recruiting Aalborg University Hospital 2021-08-01
NCT04277832 Evaluating of New Screening Tool for Arthritis* in Psoriasis https://ClinicalTrials.gov/show/NCT04277832 Recruiting Bezmialem Vakif University 2020-08-31
NCT04191395 Evolution and Treatments of Chronic Inflammatory Systemic Diseases https://ClinicalTrials.gov/show/NCT04191395 Recruiting Centre Hospitalier Universitaire de Besancon 2029-12-31
NCT04190758 GOTHA - The Early Arthritis and Psoriasis Study of Region Västra Götaland, Sweden https://ClinicalTrials.gov/show/NCT04190758 Recruiting Vastra Gotaland Region 2039-12-31
NCT04190108 Frequency of Elevated Fecal Calprotectin Levels in Psoriatic Arthritis. https://ClinicalTrials.gov/show/NCT04190108 Completed Hospital of Prato 2018-12-31
NCT04089514 A Real-world Study of Imraldi® Use https://ClinicalTrials.gov/show/NCT04089514 Recruiting Biogen 2021-06-30
NCT03986918 Survivorship and Patient Outcomes of Primary Total Hip Arthroplasty With the Ovation Hip System https://ClinicalTrials.gov/show/NCT03986918 Recruiting Ortho Development Corporation 2023-06-30
NCT03955861 Ultrasound Enthesitis Response in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03955861 Recruiting Belfast Health and Social Care Trust 2020-02-29
NCT03953378 CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03953378 Completed Hospices Civils de Lyon 2018-12-31
NCT03885089 Infliximab Biosimilar for Intravenous Drip Infusion 100 mg “Pfizer” Drug Use Investigation (Psoriasis) https://ClinicalTrials.gov/show/NCT03885089 Recruiting Pfizer 2023-03-13
NCT03835780 The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study https://ClinicalTrials.gov/show/NCT03835780 Completed Momentum Data 2019-08-01
NCT03828045 A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment https://ClinicalTrials.gov/show/NCT03828045 Recruiting Amgen 2020-08-06
NCT03816917 Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral https://ClinicalTrials.gov/show/NCT03816917 Enrolling by invitation Radboud University 2021-12-01
NCT03780504 Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece https://ClinicalTrials.gov/show/NCT03780504 Recruiting Genesis Pharma S.A. 2020-10-01
NCT03768271 APACHE Cohort (A Psoriatic Arthritis CoHort) https://ClinicalTrials.gov/show/NCT03768271 Recruiting Assistance Publique - Hôpitaux de Paris 2026-03-01
NCT03662919 One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study https://ClinicalTrials.gov/show/NCT03662919 Recruiting Biogen 2022-06-30
NCT03620188 Treatment Goals in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03620188 Active, not recruiting Johns Hopkins University 2020-12-31
NCT03608657 Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE https://ClinicalTrials.gov/show/NCT03608657 Active, not recruiting Amgen 2021-02-21
NCT03533569 Early Biomarkers for ARthritic PAIN to Guide Improved Treatments for Arthritis https://ClinicalTrials.gov/show/NCT03533569 Recruiting St George’s, University of London 2021-04-02
NCT03531073 Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03531073 Recruiting University of Oxford 2023-04-30
NCT03496831 Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs https://ClinicalTrials.gov/show/NCT03496831 Completed Rigshospitalet, Denmark 2017-12-31
NCT03452735 Fertility Study of Women With Chronic Inflammatory Rheumatism https://ClinicalTrials.gov/show/NCT03452735 Recruiting University Hospital, Toulouse 2019-07-31
NCT03419143 Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants https://ClinicalTrials.gov/show/NCT03419143 Recruiting Bristol-Myers Squibb 2020-03-30
NCT03411057 Mindfulness Based Stress Reduction in Rheumatic Diseases https://ClinicalTrials.gov/show/NCT03411057 Enrolling by invitation Johns Hopkins University 2021-01-18
NCT01163916 Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care https://ClinicalTrials.gov/show/NCT01163916 Completed Abbott 2011-11-30
NCT01155570 Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation) https://ClinicalTrials.gov/show/NCT01155570 Completed AbbVie 2012-07-31
NCT01139918 Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01139918 Completed Innovaderm Research Inc. 2014-07-31
NCT01123265 National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study https://ClinicalTrials.gov/show/NCT01123265 Completed University of Rochester 2014-06-30
NCT01111240 Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice https://ClinicalTrials.gov/show/NCT01111240 Completed AbbVie 2013-12-31
NCT01083693 Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs https://ClinicalTrials.gov/show/NCT01083693 Completed Abbott 2010-06-30
NCT01083121 Surveillance of Humira Injection in Korean Patients https://ClinicalTrials.gov/show/NCT01083121 Completed AbbVie 2012-06-30
NCT01081717 Golimumab Safety and Surveillance Program Using the Ingenix NHI Database https://ClinicalTrials.gov/show/NCT01081717 Completed Janssen Biotech, Inc. 2015-05-31
NCT01078402 EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries https://ClinicalTrials.gov/show/NCT01078402 Completed AbbVie 2011-11-30
NCT01060098 T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade https://ClinicalTrials.gov/show/NCT01060098 Completed Imperial College London 2012-12-31
NCT00998829 Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis https://ClinicalTrials.gov/show/NCT00998829 Completed Pfizer 2012-05-31
NCT00963313 A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00963313 Completed Instituto de Investigacion Biomedica de A Coruna 2012-06-30
NCT00938015 Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00938015 Completed Pfizer 2012-04-30
NCT00902005 Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment https://ClinicalTrials.gov/show/NCT00902005 Completed Revmatismesykehuset AS 2011-06-30
NCT00884468 Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00884468 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2008-12-31
NCT03096990 A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium https://ClinicalTrials.gov/show/NCT03096990 Completed Amgen 2018-12-27
NCT02627768 A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT02627768 Active, not recruiting Janssen Pharmaceutica N.V., Belgium 2021-06-30
NCT01078558 A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct ) https://ClinicalTrials.gov/show/NCT01078558 Completed AbbVie 2018-01-11
NCT00760669 An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants https://ClinicalTrials.gov/show/NCT00760669 Completed Janssen Korea, Ltd., Korea 2011-04-30
NCT00751387 Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Australia https://ClinicalTrials.gov/show/NCT00751387 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2009-09-30
NCT00741793 Biologic Treatment Registry Across Canada https://ClinicalTrials.gov/show/NCT00741793 Completed Janssen Inc. 2018-06-27
NCT00727298 Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840) https://ClinicalTrials.gov/show/NCT00727298 Completed Merck Sharp & Dohme Corp. 2011-08-31
NCT00725296 Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264) https://ClinicalTrials.gov/show/NCT00725296 Completed Merck Sharp & Dohme Corp. 2010-07-31
NCT00683384 Study Evaluating the Safety of Enbrel (Etanercept) https://ClinicalTrials.gov/show/NCT00683384 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2009-10-31
NCT00658827 Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis https://ClinicalTrials.gov/show/NCT00658827 Completed Janssen Biotech, Inc. 2016-09-30
NCT00580632 Study Evaluating Workload, Clinical and Therapeutic Management of Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00580632 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2007-09-30
NCT00451243 Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment https://ClinicalTrials.gov/show/NCT00451243 Completed National Taiwan University Hospital NA
NCT00303186 Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy https://ClinicalTrials.gov/show/NCT00303186 Completed Pfizer 2011-06-30
NCT00293722 Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists https://ClinicalTrials.gov/show/NCT00293722 Completed Pfizer 2013-02-28
NCT00293709 Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists https://ClinicalTrials.gov/show/NCT00293709 Completed Pfizer 2013-02-28
NCT00195377 Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain https://ClinicalTrials.gov/show/NCT00195377 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2006-04-30
NCT00001291 Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions https://ClinicalTrials.gov/show/NCT00001291 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001420 Study of Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00001420 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03374527 Recirculating Memory T Cells in the Pathogenesis of Psoriatic Arthritis and Cutaneous Psoriasis https://ClinicalTrials.gov/show/NCT03374527 Completed Istituto Ortopedico Galeazzi 2018-01-30
NCT03214263 Identification of New Biomarkers to Promote Personalized Treatment of Patients With Inflammatory Rheumatic Diseases https://ClinicalTrials.gov/show/NCT03214263 Recruiting Rigshospitalet, Denmark 2024-12-31
NCT03119805 Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective. https://ClinicalTrials.gov/show/NCT03119805 Completed Groupe Hospitalier Pitie-Salpetriere 2018-01-30
NCT02775500 Apremilast Pregnancy Exposure Registry https://ClinicalTrials.gov/show/NCT02775500 Recruiting University of California, San Diego 2022-02-28
NCT02530268 The Corrona Psoriatic Arthritis and Spondyloarthritis (PsA-SpA) Registry https://ClinicalTrials.gov/show/NCT02530268 Enrolling by invitation Corrona, LLC. 2100-12-31
NCT02103361 Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project https://ClinicalTrials.gov/show/NCT02103361 Recruiting University of California, San Diego 2024-12-31
NCT01965132 Korean College of Rheumatology Biologics Registry https://ClinicalTrials.gov/show/NCT01965132 Recruiting Seoul National University Hospital 2024-12-31
NCT01848028 PsoBest - The German Psoriasis Registry https://ClinicalTrials.gov/show/NCT01848028 Recruiting Universitätsklinikum Hamburg-Eppendorf 2025-12-31
NCT04347798 IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT https://ClinicalTrials.gov/show/NCT04347798 Enrolling by invitation University of Alberta 2021-04-30
NCT03470688 Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents https://ClinicalTrials.gov/show/NCT03470688 Recruiting Opal Rheumatology Ltd. 2021-06-01
NCT03456206 Chronic Inflammatory Disease, Lifestyle and Risk of Disease https://ClinicalTrials.gov/show/NCT03456206 Active, not recruiting University of Southern Denmark 2019-07-01
NCT03840928 AR-Power Patient Powered Research Network https://ClinicalTrials.gov/show/NCT03840928 Recruiting Global Healthy Living Foundation 2025-03-01
NCT03173144 Chronic Inflammatory Disease, Lifestyle and Treatment Response https://ClinicalTrials.gov/show/NCT03173144 Recruiting University of Southern Denmark 2019-03-31
NCT04402086 Rheumatology Patient Registry and Biorepository https://ClinicalTrials.gov/show/NCT04402086 Recruiting Yale University 2030-06-01